VYNE Therapeutics (VYNE) Other Non-Current Liabilities (2016 - 2024)
VYNE Therapeutics (VYNE) posted Other Non-Current Liabilities of $1.3 million for Q1 2024, down 0.99% on a QoQ basis from $1.3 million in Q4 2023, and little changed year-over-year from $1.3 million in Q2 2023.
VYNE Therapeutics (VYNE) Other Non-Current Liabilities (2016 - 2024) Analysis & Trends
VYNE Therapeutics' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $1.3 million for Q1 2024.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $1.3 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $1.3 million (changed 0.0% YoY) and the FY2023 annual result came in at $1.3 million, changed N/A from the prior year.
- Other Non-Current Liabilities was $1.3 million for Q1 2024 at VYNE Therapeutics, down from $1.3 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.3 million in Q4 2023 and bottomed at $451000.0 in Q3 2021.
- A 4-year average of $808250.0 and a median of $457000.0 in 2020 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2020 — Other Non-Current Liabilities increased 0.22% — and 2021, when it declined 1.31%.
- VYNE Therapeutics' Other Non-Current Liabilities stood at $457000.0 in 2020, then declined by 1.31% to $451000.0 in 2021, then soared by 191.13% to $1.3 million in 2023, then decreased by 0.99% to $1.3 million in 2024.
- Business Quant data shows VYNE's Other Non-Current Liabilities at $1.3 million in Q1 2024, $1.3 million in Q4 2023, and $1.3 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1.30 Mn |
| Dec 31, 2023 | 1.31 Mn |
| Sep 30, 2023 | 1.30 Mn |
| Jun 30, 2023 | 1.30 Mn |
| Mar 31, 2023 | 1.30 Mn |
| Sep 30, 2021 | 451,000.00 |
| Jun 30, 2021 | 452,000.00 |
| Mar 31, 2021 | 457,000.00 |
| Dec 31, 2020 | 457,000.00 |
| Sep 30, 2020 | 457,000.00 |
| Jun 30, 2020 | 456,000.00 |
| Mar 31, 2020 | 456,000.00 |
| Dec 31, 2019 | 456,000.00 |
| Dec 31, 2018 | 7,000.00 |
| Sep 30, 2018 | 12,000.00 |
| Jun 30, 2018 | 78,000.00 |
| Mar 31, 2018 | 20,000.00 |
| Dec 31, 2017 | 22,000.00 |
| Dec 31, 2016 | 57,000.00 |